Updates are available Correction dated 2023-03-13
Click to view Correction: https://doi.org/10.1007/s00415-023-11646-w
-
Authors
De Rosa, Alessandro Pasquale
Esposito, Fabrizio https://orcid.org/0000-0002-5099-9786
Valsasina, Paola
d’Ambrosio, Alessandro
Bisecco, Alvino
Rocca, Maria A.
Tommasin, Silvia
Marzi, Chiara
De Stefano, Nicola
Battaglini, Marco
Pantano, Patrizia
Cirillo, Mario
Tedeschi, Gioacchino
Filippi, Massimo
Gallo, Antonio
,
Altieri, Manuela
Borgo, Riccardo
Capuano, Rocco
Storelli, Loredana
Pagani, Elisabetta
Sibilia, Mauro
Piervincenzi, Claudia
Ruggieri, Serena
Petsas, Nikolaos
Cortese, Rosa
Stromillo, Maria Laura
-
Funding
Funding for this research was provided by:
Università degli Studi della Campania Luigi Vanvitelli
- License Information
-
More Information
Article History
Received: 25 September 2022
Revised: 3 November 2022
Accepted: 4 November 2022
First Online: 9 November 2022
Change Date: 13 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-023-11646-w
Declarations
:
: A.P. De Rosa, F. Esposito, P. Valsasina, A. d’Ambrosio, A. Bisecco, S. Tommasin, M. Battaglini, P. Pantano, M. Cirillo, and A. Gallo have nothing to disclose. M.A. Rocca received speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva and research support from the Canadian MS Society and Fondazione Italiana Sclerosi Multipla. M. Filippi is the Editor-in-Chief of the Journal of Neurology and Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology, received compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries, and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, the Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). G. Tedeschi received funding for travel, speaking honorarium, consulting service, and research projects from Novartis, Genzyme, Teva, Merck, Biogen, Roche, Allergan, Abbvie, Lilly, and Mylan. N. De Stefano has received honoraria from Biogen-Idec, Celgene, Immunic, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva for consulting services, speaking, and travel support. N. De Stefano serves on advisory boards for Biogen-Idec, Immunic, Merck Serono, Novartis, Roche, and Sanofi-Genzyme. N. De Stefano has received research grant support from the Italian Multiple Sclerosis Society.
: Ethical approval was received from the local ethical standards committee of each participating Center, and written informed consent was obtained from all participants at the time of data acquisition.
: All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians.
